ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2544

Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy

Xiaoxia Jia1, Fang Li2, Jing Luo3, Chong Gao4 and Xiao-Feng Li1, 1Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, 2Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, 3the Second Hospital of Shanxi Medical University, Taiyuan, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: CD8 cells, immunoregulation, interleukins (IL) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Recent studies have showed that quantitative and/or functional abnormalities of the regulatory T cells (Tregs) may play a vital role in the development of rheumatoid arthritis (RA). It is reported that CD25+FOXP3+T cells include CD4+CD25+FOXP3+T (CD4+Tregs) and CD8+CD25+FOXP3+T cells (CD8+ Tregs). CD8+Tregs also have been showed even stronger immunosuppressive function and more sensitive to IL-2 than CD4+Tregs in vivo.

Our study was designed to clarify the level of peripheral CD8+T cell subsets in RA patients, especially CD4–(CD8+)CD25+FOXP3+T cells, and to investigate the role of recombinant human interleukin-2 (IL-2) in the regulation of CD4–(CD8+)CD25+FOXP3+ T cells in RA patients to provide a basis to IL-2 therapy.

Methods:

Total 231 Patients with RA were enrolled, including 75 new-onset RA and 156 treated with low dose IL-2 (50 WIU/day for 5 days, subcutaneous injection), and 90 healthy adults were included as controls. The clinical data of RA patients were collected, including gender, age, joint swelling, tenderness and so on. And laboratory parameters were erythrocyte sedimentation rate (ESR), C reactive protein (CRP), rheumatoid factor(RF) and anti-cyclic citrullinated peptide antibody (Anti-CCP). At the same time, the DAS28 score of RA group was calculated. The absolute number of CD4–CD25+FOXP3+ T cells in peripheral blood were detected by flow cytometry. We assume that CD4– T cells with CD25+ and FOXP3+ were mostly CD8+CD25+FOXP3+ T cells, i.e. 8+Tregs.

Results:

As compared with the healthy controls, the absolute number of CD8+ Treg cells decreased significantly in the new-onset RA patients [0.92(0.42,1.39) vs 1.31(0.72,2.52), P <0.001]. The absolute number of CD8+Treg cells was significantly negative correlated with tenderness joints, DAS28 score and RF, (r=-0.249, P=0.032; r=-0.294, P=0.010; r=-0.365, P=0.001); The absolute number of CD8+ Treg cells was no significantly correlated the swelling of the joints, ESR, CRP, Anti-CCP antibody (r=-0.199, P=0.087; r=-0.202, P=0.082; r=0.008, P=0.947; r=-0.083, P=0.480). After treatment with IL-2, the absolute number of CD8+ Treg cells increased significantly as compared with that before treatment [0.88(0.42,1.51) vs 1.98(0.91,3.37), P<0.001].

Conclusion:

The absolute number of CD8+ Treg cells in initial diagnosed patients was lower than that of healthy controls, implying that the immunosuppressive function was attenuated by disease itself, rather than immunosuppression therapy, which may be an important factor in the pathogenesis of RA. Low dose IL-2 can expand CD8+Treg cells in peripheral blood, and thereby improve the immune function, so that RA patients were relieved. We are about to detect CD8+Treg cells using more accurate technique to verify this theory.


Disclosure: X. Jia, None; F. Li, None; J. Luo, None; C. Gao, None; X. F. Li, None.

To cite this abstract in AMA style:

Jia X, Li F, Luo J, Gao C, Li XF. Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/changes-of-cd4-cd8-regulatory-t-cells-in-rheumatoid-arthritis-patients-and-during-interleukin-2-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-of-cd4-cd8-regulatory-t-cells-in-rheumatoid-arthritis-patients-and-during-interleukin-2-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology